TCTMD - tctmd.com
There is a growing recognition of the prevalence and outcomes associated with tricuspid regurgitation, whether in isolation or with concomitant diseases. This program will focus on defining the burden of disease, outlining current guideline directed medical therapy and discussing the recent evidence for transcatheter therapies.
TCT 2023 - TCTMD.com
2023年10月23日 · TCT 378: A novel miRNA nanocarrier for local device-based pharmacotherapy. October 26, 2023. Presentation TCT 2023.
Welcome to TCTMD | tctmd.com
On behalf of CRF and TCTMD, we would like to extend a warm welcome to our community, which has developed over the past 20 years around a common goal to improve the survival and quality of life for people living with cardiovascular disease through research and education. We look forward to seeing you at our conferences and to working together to ...
News | tctmd.com
2024年10月7日 · First dedicated leaflet modification device to enable TAVR in patients at risk of coronary obstruction. Positive changes in prognostic biomarkers including infarct size, left ventricular dimensions and NT-proBNP level support the anti-remodeling effect of ProtheraCytes cell therapy in post-myocardial infarction patients at risk of heart failure.
Slides | tctmd.com
2024年4月8日 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
Will Semaglutide Change Cardiac Surgery? It Already Has
4 天之前 · Sigrid Sandner, MD (Medical University of Vienna, Austria), who co-chaired the session, is also a believer, telling TCTMD that semaglutide will “absolutely” change the landscape of cardiac surgical practice. Other cardiac surgeons, however, might not fully appreciate how the advent of these powerful medications will affect their practice ...
Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows
5 天之前 · A sizeable portion of patients had CV risk factors, including diabetes in 12.5%, hypertension in 37.5%, hypercholesterolemia in 32%, and a smoking history in 35%. The pooled prevalence of CV complications was lowest for MI at 0.62%, followed by CV death at 0.63% and HF events at 3.87%. Pooled prevalence rates of supraventricular arrhythmia were ...
APPRAISE ATP Highlights the Trade-offs of Antitachycardia Pacing
5 天之前 · Schuger pointed out that the APPRAISE ATP results indicate that antitachycardia pacing is not as effective at terminating ventricular arrhythmias as indicated by prior trials. ATP terminated the arrhythmias in 54% of cases in the current trial, much lower than the 81% rate observed with a single ATP burst in PainFREE Rx II, which was published ...
TVT 2021 - TCTMD.com
The PARTNER 3 Bicuspid Registry for SAPIEN 3 Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. Presenter: Mathew Williams. Presentation TVT 2021. Early neo2 Registry. Full Core-lab Results of TAVI With the New …
COVID-19 TCTMD HUB | tctmd.com
Monday, December 19Delaying Surgery After COVID-19 Cuts Risk of CV Complications. The researchers say it’s best to calculate the risks and benefits, rather than define an optimal time for surgery post-COVID.